Part 6/8:
Sarepta's potential drug not only raises questions about its efficacy but also about its affordability. In a landscape dominated by high-priced medications for rare diseases, the new treatment for DMD is anticipated to carry a hefty price tag. Given the limited patient population—approximately 50,000 affected globally, with only 5,000 to 6,000 potentially benefiting from this specific treatment—investors must consider whether the current stock price has already factored in the drug's chances of approval.